More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

“Oh my God, you don’t need it.” “I’ve gained 20 pounds since going into menopause, all in my gut!” “It’s for people with ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Canaccord raised the firm’s price target on Hims & Hers to $68 from $38 and keeps a Buy rating on the shares. Thefirm noted shares are up ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

BTIG analyst David Larsen raised the firm’s price target on Hims & Hers (HIMS) to $85 from $35 and keeps a Buy rating on the shares. The ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...